In recent years, candidate cellular pathways such as CDK4/CDK6, IGF-IR, PI3K/AKT/mTOR, and MAPK have played a role in the development of anti-estrogen therapy resistance of BC and are proven targets for the development of new therapeutic strategies. This evidence concerns the gene IGF1R and breast cancer.